Emerging Regulations of AI – The Impact on Pharma R&D

When

JavaScript Disabled
JavaScript Disabled
(Date and time are shown in your browser's local time zone)

Event Type

Most recently both the EU and the US announced new legislation aiming to regulate the development and use of Artificial Intelligence: the EU AI Act and the President Biden Executive Order on the Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence. Our panel of experts will discuss how these legal changes may affect research and development in drug discovery.

Agenda (please note these are in GMT times)

16:00    Introductions

Vladimir Makarov, Project Manager, Pistoia Alliance 

16:05    How is AI used in your organization?

16.10    Review of current and proposed regulations

  • Frederik van den Broek, Senior Director, Professional Services and Consulting, Elsevier

16:25    Panel Discussion with our speakers

  • Frederik van den Broek, Senior Director, Professional Services and Consulting, Elsevier
  • Koen Cobbaert, Senior Manager – Quality, Standards & Regulations, Philips
  • Sophie Ollivier, Chief Data Officer R&D, Servier
  • Gideon Rosenthal, Head of Research, Data Science Group

16:55    Closing Remarks and next steps

17:00    Close

 

Register below